| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $6.2M | +120.6% |
| R&D Expense | $83.1M | +153.1% |
| SG&A Expense | $25.0M | +37.6% |
| Operating Income | -$101.9M | -111.5% |
| Income Tax | $0 | — |
| Net Income | -$85.0M | -95.1% |
| EPS (Basic) | -$2.55 | +69.8% |
| EPS (Diluted) | -$2.55 | +69.8% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $22.8M | -82.8% |
| Short-term Investments | $252.4M | +509.9% |
| Accounts Receivable | $807K | +174.5% |
| Current Assets | $280.9M | +58.3% |
| Total Assets | $374.0M | +108.5% |
| Current Liabilities | $18.5M | +91.6% |
| Total Liabilities | $21.5M | +104.4% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$78.2M | -112.1% |
| Capital Expenditures | $105K | -4.5% |
| Investing Cash Flow | -$286.8M | -1516.1% |
| Financing Cash Flow | $255.6M | +91.4% |
| Free Cash Flow | -$78.3M | -111.7% |
| Stockholders' Equity |
| $352.5M |
| +108.7% |